Galectin Therapeutics (GALT) Convertible Debt (2021 - 2026)

Galectin Therapeutics' Convertible Debt history runs 6 years deep, the most recent figure standing at $32.9 million for Q1 2026.

• In Q1 2026, Convertible Debt rose 204.06% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $32.9 million (up 204.06% YoY), while the FY2025 annual figure was $32.7 million, up 204.69% from the prior year.
• Convertible Debt for Q1 2026 stood at $32.9 million, up from $32.7 million in the prior quarter.
• The five-year high for Convertible Debt was $32.9 million in Q1 2026, with the low at $10.7 million in Q4 2024.
• The 5-year median for Convertible Debt is $30.3 million (2023), against an average of $27.7 million.
• The sharpest annual moves came in 2022 and 2025: Convertible Debt soared 205.96% in 2022, then plunged 65.28% in 2025.
• Galectin Therapeutics' Convertible Debt stood at $30.0 million in 2022, then climbed by 3.13% to $30.9 million in 2023, then plunged by 65.27% to $10.7 million in 2024, then surged by 204.69% to $32.7 million in 2025, then advanced by 0.54% to $32.9 million in 2026.
• Business Quant data shows GALT's Convertible Debt at $32.9 million in Q1 2026, $32.7 million in Q4 2025, and $32.3 million in Q2 2025.